Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Chapter
  • Print publication year: 2009
  • Online publication date: May 2010

Chapter 32 - Analyzing male fertility data

Export citation
Summary
This chapter reviews the empiric therapies available today for male infertility and discusses their mode of action. It reviews published literature on outcomes available and analyzes the evidence for use and dosing recommendations. With the exception of low-dose vitamin supplementation and aromatase inhibitors, empiric therapy is seldom recommended in the treatment of the infertile male. Gonadotropin-releasing hormone (GnRH) stimulates the synthesis and release of the gonadotropic hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), in the anterior pituitary. Treatment of hypogonadotropic hypogonadism with exogenous gonadotropins or GnRH has produced good results compared with treatment of other male infertility problems. Exogenous testosterone therapy can produce azoospermia or severe oligospermia through the inhibition of gonadotropin secretion. Glutathione therapy has been used in various pathologic conditions in which reactive oxygen species are thought to play a pathogenic role. Administration of high-dose antioxidants has a potential beneficial effect on male fertility.

Keywords:

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Infertility in the Male
  • Online ISBN: 9780511635656
  • Book DOI: https://doi.org/10.1017/CBO9780511635656
Please enter your name
Please enter a valid email address
Who would you like to send this to *

CAPTCHA *

Skip to the audio challenge
×

References

[1] BairdDT, CollinsJ, EgozcueJ, et al.; ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Update 2005; 11: 261–76.
[2] NiederbergerC, MakhloufAA. Vasectomy reversal in the presence of diminished ovarian reserve: a complex clinical conundrum. J Androl 2006; 27: 3–5.
[3] US Department of Health, and Human Services, Centers for Disease Control, and Prevention. Assisted Reproductive Technology Success Rates, National Summary and Fertility Clinic Reports. Atlanta, GA: CDC, 2005. www.cdc.gov/ART/ART2003.
[4] ShinD, HonigSC. Economics of treatments for male infertility. Urol Clin North Am 2002; 29: 841–53.
[5] KolettisPN, SabaneghES, NalesnikJG, et al. Pregnancy outcomes after vasectomy reversal for female partners 35 years old or older. J Urol 2003; 169: 2250–2.
[6] HeidenreichA, AltmannP, EngelmannUH. Microsurgical vasovasostomy versus microsurgical epididymal sperm aspiration/testicular extraction of sperm combined with intracytoplasmic sperm injection: a cost-benefit analysis. Eur Urol 2000; 37: 609–14.
[7] DeckAJ, BergerRE. Should vasectomy reversal be performed in men with older female partners? J Urol 2000; 163: 105–6.
[8] PavlovichCP, SchlegelPN. Fertility options after vasectomy: a cost-effectiveness analysis. Fertil Steril 1997 Jan; 67: 133–41.
[9] AltmanDG, BlandJM. Diagnostic tests 2: predictive values. BMJ 1994; 309: 102.
[10] JarowJP, SharlipID, BelkerAM, et al. Male Infertility Best Practice Policy Committee of the American Urological Association, Inc. Best practice policies for male infertility. J Urol 2002; 167: 2138–44.
[11] NiederbergerCS. Understanding the epidemiology of fertility treatments. Urol Clin North Am 2002; 29: 829–40.
[12] ZweigMH, CampbellG. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561–77.
[13] MacLeodJ. Semen quality in 1000 men of known fertility and in 800 cases of infertile marriage. Fertil Steril 1951; 2: 115–39.
[14] GuzickDS, OverstreetJW, Factor-LitvakP, et al. Sperm morphology, motility, and concentration in fertile and infertile men. N Engl J Med 2001; 345: 1388–93.
[15] HellstromWJ, OverstreetJW, SikkaSC, et al. Semen and sperm reference ranges for men 45 years of age and older. J Androl 2006; 27: 421–8.
[16] MakhloufAA, NiederbergerC. DNA integrity tests in clinical practice: it is not a simple matter of black and white (or red and green). J Androl 2006; 27: 316–23.
[17] GaltonF. Regression towards mediocrity in hereditary stature. J Anthropol Inst 1886; 15: 246–63.
[18] BlandJM, AltmanDG. Regression towards the mean. BMJ 1994; 308: 1499.
[19] TsujimuraA, MatsumiyaK, MiyagawaY, et al. Prediction of successful outcome of microdissection testicular sperm extraction in men with idiopathic nonobstructive azoospermia. J Urol 2004; 172: 1944–7.
[20] WaldM, SparksAET, SandlowJ, et al. Computational models for prediction of IVF/ICSI outcomes with surgically retrieved spermatozoa. Reprod Biomed Online 2005; 11: 325–31.
[21] ParekattilSJ, KuangW, KolettisPN, et al. Multi-institutional validation of vasectomy reversal predictor. J Urol 2006; 175: 247–9.
Cancel
Confirm
×